Tech Company Financing Transactions
Lifordi Immunotherapeutics Funding Round
5AM Ventures, Arch Venture Partners and Atlas Venture participated in a funding round for Lifordi Immunotherapeutics. The financing was announced on 11/19/2025.
Transaction Overview
Company Name
Announced On
11/19/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to support the ongoing Phase 1 study in Rheumatoid Arthritis (RA) designed to evaluate LFD-200, an ADC delivering a new glucocorticoid (GC) directly to immune cells.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Burlington, MA Undisclosed
USA
Burlington, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Developing new therapies for autoimmune and inflammatory disorders using a novel, targeted ADC based delivery platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arthur Tzianabos
Browse more venture capital transactions:
Prev: 11/19/2025: Emm venture capital transaction
Next: 11/19/2025: Amperesand venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. All VC database entries reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs